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Abstract 
Objectives 
To explore the current use of injection therapy as part of a conservative treatment plan for degenerative meniscal 
lesions (DML) within UK Based Physiotherapy Members of the Society of Musculoskeletal Medicine (SOMM) 
with Injection Training. 
Methods 
An online survey was distributed via email to all UK based, SOMM physiotherapists who had trained and 
received their injection diploma through the SOMM (n=203) with a response rate of 32% (n=64). The data was 
analysed using descriptive statistics, contingency tables and the Fisher’s exact test. A p value ≤0.05 was 
considered significant. Ethical clearance was gained through the SOMM and Middlesex University. 
Results 
Of the respondents 98% (n=62) of current UK based, injection trained SOMM physiotherapists utilise 
conservative treatment for DML of which 81% (n=52) include injection therapy. 77% (n=49) who currently use 
injection therapy for DML administer a combination of 40mg Depomedrone combined with local anaesthetic 
via a patellofemoral approach. 
Those not using injection therapy as part of their management of DML attributed this to local department 
restrictions and lack of evidence. 
Discussion 
This research has helped further understand the use of injection therapy for DML and where it fits within a 
conservative treatment plan. The benefit from injection therapy reported by respondents is similar to previous 
research but could be influenced by injection exposure and potentially steroid choice. Overall a consensus is 
starting to appear regarding dosage, steroid and administration; however differences are identified when 
comparing individual department guidelines to CSP and NICE guidelines.  
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Introduction 
A degenerative meniscus is a meniscus that has started to deteriorate over time, becoming 
less elastic and compliant leading to failure through minimal trauma eg: squatting or twisting 
[1]. Meniscal degeneration is common amongst the middle aged and elderly population [1]. 
Patients over the age of 45 are likely to have degenerative meniscal changes on MRI [2]. 
Occupation plays a big external factor towards DML with manual workers and athletes most 
at risk due to the increased chance of twisting the knee on a fixed foot or over pressured knee 
flexion leading to more strain on an already weakened structure [3]. With retirement age 
increasing, DML secondary to occupation is becoming increasingly common [4]. 
 
Around 80% of meniscal tears treated surgically are degenerative in nature [5]. One meniscal 
resection costs the National Health Service (NHS) around £3000. [6]. 
For degenerative menisci to be surgically treated a patient needs to present with either: A 
clinically locked knee and / or attempted and failed conservative treatment [7]. 
Unless the knee is clinically locked all other DML symptoms do not fall under the surgical 
category, therefore  conservative treatment including injection therapy should be considered 
initially [7].  
 
The outcome of injection therapy for DML is broad and vague; it can give anywhere from 3 
days to over 6 months relief. Presently it is a modality that is not widely used for DML but 
can provide as much benefit as present methods of treatment [8]. 
Musculoskeletal medicine is the examination, diagnosis and treatment of non-surgical lesions 
of the musculoskeletal system. The Society of Musculoskeletal Medicine (SOMM) - formerly 
the Society of Orthopaedic Medicine - is an educational charity that was formed in 1979 to 
develop the seminal work of Dr James Cyriax MRCP and to promote the theory and practice 
of musculoskeletal medicine. The Society provides a programme of postgraduate courses for 
physiotherapists and medical practitioners that run throughout the UK, Europe and South 
East Asia.  
Background Literature 
There has been a lot of research previously undertaken looking at the effects of injection 
therapy for knee oesteo-arthritis, however this does not cover the early stages where x-ray 
findings are clear but meniscal testing is positive but no trauma has occurred hence fitting the 
diagnosis of a DML [2]. DML can then lead to progressive degeneration of the knee joint and 
eventually osteoarthritis but if  effective treatment is available that can settle a DML at the 
early stages this can help preserve the knee and potentially prolong the degenerative process 
[8]. Previous research has shown that injection therapy is beneficial for early knee 
degeneration due to decreasing inflammation and pain [9]. These symptoms are similar if not 
identical to those of a DML therefore giving potential evidence that an injection would be 
beneficial for this patient group as well. 
 
Menisectomy is commonly used for DML and even considered the gold standard treatment 
[9] but evidence is lacking to support this. Menisectomy is starting to come under scrutiny as 
the leading treatment for DML due to appraised literature finding that it is no better than 
sham surgery or conservative treatment. In some areas, the NHS in accordance with the 
National Institute for Health and Care Excellence (NICE) are not funding arthroscopies for 
DML unless the patient has completed at least twelve months of conservative treatment, 
which has been deemed to be unsuccessful [4], agreeing with the notion that initially 
conservative treatment should be applied for this pathology and should be continued for a 
long period of time to be able to determine its effectiveness [7]. 
 
Exercise is a commonly used modality within research into DML [10-13]. All implied it was 
cost effective and available to all. However, injection therapy has not been explored to 
identify if it can match the benefits of exercise. Corticosteroid injections have been included 
as part of post-operative treatment for menisectomy in DML and found it was beneficial [10]. 
Past research has found that steroid alone is on a par with menisectomy; a combination of 
arthroscopy and steroid may have not been needed, a steroid injection alone could be the way 
forward [8]. In the short term injection is favourable over exercise because it will start to 
show benefit within one week and maximal results by three and can give benefit for an 
average of eight months [8,10], whereas exercise takes at least six weeks to start to see 
physical changes [8].  
 
Purpose and Aims 
At present the research looking at injection therapy for DML is scarce with currently only 
study conducted [8]. No previous surveys have been conducted to explore its use within 
practicing clinicians. The aim of this research was to; explore the current use of injection 
therapy as part of a conservative treatment plan for DML within UK based, injection trained 
SOMM physiotherapists. 
 
Study Methodology 
An online generated survey (Appendix 1) was conducted to gain a clearer understanding of 
current UK based, SOMM injection trained physiotherapy members utilisation of injection 
therapy as part of a conservative treatment plan for DML. The participants (n=203) were a 
mixture of National Health Service (NHS), private practice and sports based physiotherapists. 
Ethical approval was gained through the Middlesex University and the SOMM research 
committee. All participants were recruited in their capacity as SOMM members and not NHS 
employees. 
 
Population and Sampling 
A specific inclusion criterion was applied, incorporating current physiotherapists that were: 
SOMM members who were injection therapy trained by the SOMM and reside and work 
within the UK. This criterion ensured all participant answers were directly linked to this 
research and ensured the purposive sample was obtained and variables were kept to a 
minimum to enable greater comparison and analysis. Current members of one society and 
injection training from that society, removed any variance in training the participants would 
have received, which would help them answer the survey reducing any intra-question 
discrepancies and enabled the results gained to be of current thoughts and practice which 
allowed comparison to current guidelines and policies and created a picture of how injection 
therapy is being used presently for DML [14].   
 
Survey 
A pilot survey was generated and distributed to 5 SOMM physiotherapists with a speciality in 
injection therapy and/ or knee rehabilitation to ensure a broad range of feedback. They were 
given the hard copy of the survey and asked to comment on ease of completion, quality of 
content, general presentation and ability to transfer this to a user friendly online version. 
Subjective feedback was recorded, no standardises marking schemes were used. The main 
aspect the feedback highlighted was the need for consent evidence. Other changes were to 
question structure and overall presentation. The main survey was distributed alongside an 
information sheet. From initial distribution, all participants had six weeks to complete and 
return the survey. To increase participation a reminder email was sent out after two and five 
weeks. 
 
Data Analysis 
All data collected was quantitative, the demographic questions provided continuous data but 
the majority was categorical [14].  
Demographic and geographic information was collected to help apply the inclusion criteria 
and used as a basis of comparison for more specific questions.  
The data was analysed using the Fisher’s exact test via the online statistical programme 
GraphPad [15]. An associated “p” value of ≤ 0.05 was considered significant [14]. 
 
Findings 
There are currently 210 UK based physiotherapists who are members of the SOMM and have 
trained and received their injection therapy diploma through the SOMM. In May 2015 the 
main survey was distributed for six weeks to 203 participants: seven participants were 
discarded due to their involvement either via the pilot study or direct link to the research 
planning. The response rate was 32% (n=64). A demographic overview can be seen in (Table 
1). Consent was gained within the survey from all completed participants. A response rate of 
64 surveys ensured the data collected was statistically significant with a 10% margin of error 
[16].  
It is unlikely to get a 100% return rate [17] but 32% was lower than expected. Investigation 
into this did highlight that some emails addresses of potential participants were old and had 
not been updated on the SOMM database therefore that member may have not even received 
the survey in the first place which overall decreased the starting number. Another potential 
reason for low response rate was that this research project was part of an MSc alongside other 
colleagues who were also sending online surveys therefore there may have been crossover in 
participants who may have already completed a survey and ignored the email due to either 
thinking it was a repeat sending or did not want to complete another survey.  
 
Treatment 
This survey showed that once a DML had been diagnosed it was treated conservatively by 
94% (n=59) using a variety of methods unless surgical criteria were indicated (Fig. 1). The 
surgical criteria identified that would warrant orthopaedic referral was; if the knee was 
clinically locked on presentation and could not be unlocked manually; 88% (n=56) and/ or 
the patient asked to be referred on; 81% (n=51). 
For long-term treatment of DML; 90% (n=57) would refer on to orthopaedics if conservative 
treatment was unsuccessful within six weeks to three months of physiotherapy.  
 
Injection Therapy 
Injection therapy was used by 81% (n=52) for treating DML. No respondent used it 
independently, all combined injection therapy with exercise and at least one other 
conservative modality (p<0.019). The majority of respondents; 87% (n=55) believed that 
injection therapy could feature sometimes within the conservative treatment plan for DML.  
Injection therapy was considered beneficial towards DML by 98% (n=63) of respondents, 
with 80% (n=45) of those stipulating that it was beneficial most of the time.  
An association was identified when analysing the total number of specific knee joint 
injections administered per month. 74% (n=34) of those that felt injection therapy was 
beneficial most or all of the time for DML injected three or more knees per month, whereas 
those that did not find injection therapy beneficial for DML; 70% (n=7) only injected two or 
less knees per month (p<0.007). Considering the 19% (n=12) that did not use injection 
therapy for DML, the main reasons stipulated were; unable to inject due to current workplace 
guidelines and not enough evidence towards injection therapy being beneficial for DML (Fig. 
2). However, 50% (n=6) of those, stated they would start to use injection therapy for DML if 
their workplace restrictions were resolved. 
 
Further analysis was undertaken, outlining the variances in injection therapy technique and 
procedure, between participants who currently used it for DML (n=56).  
The main dosage of steroid chosen was 40mg; 88% (n=49), there was an association 
identified between the dosage used and injection therapy experience, with 92% (n=45) of 
those that used 40mg had 0-5 years’ experience (p<0.008). All respondents who currently 
inject for DML used one of two types of steroid; Depomedrone; 70% (n=39) and Kenalog; 
30% (n=17). Only 7% (n=4) injected steroid only, the rest combined it with local anaesthetic. 
When administering the injection, 93% (n=52) stated they used a medial patella approach, 
68% (n=38) a lateral patella approach and 45% (n=25) through the anterior portals of the 
knee. Only 2% (n=1) injected through the actual joint line of the knee. It was identified that 
each participant used at least two of the four approaches. There was no statistical association 
between the type of approach used and SOMM and/ or injection therapy experience.  
When cross tabulating this information it was observed that from the 73% (n=47) that found 
injection therapy to be of some kind of benefit for DML, 77% (n=36) used a combination of 
40mg of Depomedrone, combined with local anaesthetic, via a patella femoral approach 
(p<0.01). All who found injection therapy beneficial for DML used at least one variable from 
this stated combination, however, of the 27% (n=17) that did not find injection therapy 
beneficial for DML, it was observed that all had used Kenalog and deviated from the above 
combination by at least 2 variables.  
 
There were a variety of reasons advocated by injection trained, SOMM physiotherapists 
towards why injection therapy was beneficial for DML (Fig. 3). 
From all respondents, 50% (n=32) believed that the injection therapy was directly influencing 
the DML whereas the other 50% felt that the symptoms were more likely to be caused by an 
overall arthritic knee which the DML was a secondary problem to, so the injection was 
primarily targeted at having a positive effect on the underlying arthritic changes. 
 
After injecting, all respondents reviewed the patient at a later date, with 61% (n=34) waiting 
at least five weeks before reviewing. At the review appointment if the patient had no benefit 
from the first injection, 62% (n=35) would re-inject. However the majority 80% (n=45) 
advocated if the injection had been sufficiently beneficial so the patient could self-manage, 
they would advise the patient to continue with the aid of other conservative treatment first but 
re-inject if the problem worsened. 
No re-injection at the review appointment was advocated by 38% (n=22), of those 48% 
(n=10) would use other conservative treatment and 38% (n=8) would refer to orthopaedics. 
Analysing long-term injection therapy for DML, all injection trained SOMM physiotherapists 
stated they would inject the same knee up to three times a year. The same knee would be 
injected more than three times a year by 61% (n=34) if the injections were beneficial and the 
patient was not fit for surgical intervention. Of the remaining 39% (n=23), 65% (n=15) would 
refer to orthopaedics and 30% (n=7) would concentrate on other conservative treatment. 
 
Discussion 
Treatment 
The current gold standard treatment for DML is menisectomy [9], but the latest appraised 
research has found that it is not better than a conservative treatment plan. Respondents to the 
survey are treating DML conservatively unless surgical criteria is indicated and when 
analysed further the surgical criteria they follow correlates with current research [7]. 
The most common conservative treatments currently used for DML by injection trained, UK 
based SOMM physiotherapists were exercise (98%) and advice (94%). This fits with the 
previous research where over half of the studies that analysed conservative treatment for 
DML used exercise therapy as their modality and found it to be just as good if not better than 
surgical intervention in regards to pain, function and long term outcome [1,11,13,18-20]. A 
limitation of exercise is that is puts most of the emphasis on the patient, the past research has 
shown when part of a physiotherapy led group programme, exercise gives positive results 
both mentally and physically [18] but when the patients are then left with home exercise 
programmes, regression was identified. 
The current surgical criteria [7] advocates that unsuccessful conservative treatment is an 
indication to refer a DML patient on for orthopaedic surgical consultation, however it does 
not stipulate how long treatment should be applied to be deemed as unsuccessful. Past 
research states that at least 12 months of treatment should be applied before funding will be 
granted if surgical intervention is required [4]. Current UK based injection trained SOMM 
physiotherapists are applying conservative treatment before referring on, but this application 
is only between two to six months which is too early when analysed against the past research 
[4]. Further research needs to be performed to follow up these referrals and determine if they 
were assessed by an orthopaedic consultant, if surgical intervention was performed and if yes, 
was this due to the patient or external factors eg: geography, to determine if the current 
surgical criteria stipulations [7] can be quantified. 
One aspect of referring patients on for orthopaedic consultation identified through this survey 
that differs to current guidance [7] was the patient asked to be referred. No previous study 
allowed patients to request which treatment they would like and three studies advocated that 
patients who were undertaking conservative treatment could ask to have surgery at a specific 
point in the study, but it did not give details of whether each patient was granted this request, 
and if not, whether they withdrew for that reason. The NHS, Health Care Professions Council 
(HCPC) and the Chartered Society of Physiotherapists (CSP) all advocate patient centred care 
but patients requesting surgery can potentially been seen as patient led not patient centred. 
Patient centred care ensures the patient is involved in the decision making process of their 
treatment but it is the health care professionals that are leading the options [19]. Respondents 
with more experience were identified to be more likely to refer on if the patient asked, 
however, physiotherapists cannot refer patients on just because they request, it does not fit 
with evidence-based practice [3] and would cause a breakdown in effective referrals to 
orthopaedic consultants.  
 
Injection Therapy 
Depomedrone and Kenalog were the only types of steroid being used by injection trained, 
UK based, SOMM physiotherapists for this pathology.  
Those that found injection therapy beneficial all the time for DML administered 
Depomedrone compared to those that did not find injection therapy beneficial at all for DML 
who administered Kenalog. Kenalog was not found to be completely negative; those that 
found injection therapy partially beneficial for DML had used both Depomedrone and 
Kenalog. Anecdotal evidence has shown that the administration of Kenalog has provided 
benefit for DML. This is backed by reviews [21-22], that appraised studies looking at the use 
of injection therapy for knee degeneration and found Depomedrone, Kenalog and other 
steroids had been used but no differences between the types were identified.  
This research now demonstrates that within current practice of a specific practitioner group, 
Depomedrone is favoured but the strength of these findings is weak when transferred into 
global injection therapy practice but it has highlighted a potential area of consideration 
regarding the future development of the treatment of DML. 
The survey identified four respondents used 20mg for DML and two used ≥ 50mg. When 
analysed further, those that used 20mg did not find injection therapy beneficial for DML and 
those that used ≥50mg had no greater benefit than 40mg. Injection therapy experience has 
been identified to alter dosage choice; those with ≤5 years injection therapy experience used 
40mg. This research has started to identify what steroid and dosage current UK based, 
injection trained SOMM physiotherapists are administering for DML but at present it is not 
strong enough to transfer these conclusions to all injection therapists. All the local guidelines 
need to be compared to determine if the current practice regarding dosage and steroid is a 
practitioner or departmental decision. 
Hyaluronic acid injections are another option within the category of injection therapy, they 
were not investigated into within this research due to this being a SOMM based MSc project 
and hyaluronic acid injections not being currently advocated within the SOMM training. Also  
these type of injections are not appropriate for solely meniscal issues [23], there needs to be 
some joint space narrowing and degeneration to the articular cartilage for hyaluronic acid 
injections to be indicated and effective which DML does not fit. For patients with just DML 
inflammation is the biggest issue therefore needs resolving, which is where a steroid injection 
becomes indicated and favourable over hyaluronic acid [23]. 
 
A favoured approach for an intra-articular knee joint injection is patellofemoral, due to easier 
ability to gain intra-articular access [8]. However a study [24] compared a patellofemoral 
joint approach to an anterior portal for intra articular knee joint injections and concluded that 
both options provided equal positive outcomes regarding pain of injection and length of 
benefit. This survey identified that a medial patella femoral approach, was used by nearly all 
respondents but nearly half also used an anterior portal approach. No links were identified 
between the type of approach and the respondents experience or other demographic 
information. The common factor was that all had gained injection therapy accreditation via 
SOMM where a patellofemoral approach is advocated hence its common transfer to practice. 
It can be concluded that current UK based, injection trained SOMM physiotherapists are 
following current SOMM guidelines regarding approach and that other options are being 
utilised.  
 
This research identified that half believed injection therapy primarily affected the DML 
whereas the other half felt the injection primarily affected an arthritic knee and the DML 
improvement was secondary. Previous research [1-2] and anecdotal evidence believe that 
DML will occur before the knee joint fully degenerates and therefore can be addressed first. 
If left untreated the DML will lead to overall knee joint degeneration, the main factor is time 
since onset. Identifying the benefits of injection therapy for patients with solely a DML 
compared to those with DML and knee joint degeneration will help conclude which benefits 
of injection therapy are specific to DML and can alter future practice by aiding practitioner 
decision of when to administer injection therapy. 
 
This research has highlighted that some respondents are finding their use of injection therapy 
for DML is restricted by departmental guidelines.  
The ability for physiotherapists to inject was granted in 1997 [25] and over the last 18 years 
the guidelines towards its use by physiotherapists have become less clear cut including the 
removal of the CSP guidelines due to age of publication and no renewal of policies. Some 
areas have created guidelines for physiotherapists to follow which dictate how to apply 
injection therapy for specific pathologies including DML [26]. This contradicts the SOMM 
guidelines [27] of injection therapy that imply they are a foundation to work from but 
independent knowledge, understanding and clinical reasoning should shape its use for each 
patient.  
This research highlighted that minimal or non-restricted injection exposure gives current UK 
based, injections trained SOMM physiotherapists the ability to use the modality as it should 
be for DML, therefore learn from it and reflect accordingly.  
 
Strengths and Limitations 
Past practice has advocated surgical intervention as the gold standard treatment for this 
pathology but research has started to show that this is not the best option and conservative 
treatment is just as good if not better. This research has identified that within current practice, 
UK based, injection trained SOMM physiotherapists are regularly using conservative 
treatment for DML with injection therapy playing a common role.  
This research only analysed a specific geographical group and profession within one society 
of injection therapy. The conclusions drawn may not be transferable to all injection therapists 
but this research can help shape future practice for a specific practitioner group, which occurs 
over the UK. By addressing DML the conclusions can be linked to the treatment plan of a 
pathology that affects a large patient group therefore greater transference into the practical 
setting and increased evidence. 
 
Implications for Practice and Future Research 
The increase in perceived positive benefits for Depomedrone compared to Kenalog is not 
backed up by past research. However, no previous studies have compared these two steroids 
for DML treatment and when reviewed all past studies regarding injection therapy for DML 
or knee osteoarthritis do no highlight a specific favoured type of steroid. More research is 
needed to determine the efficacy of Depomedrone compared to Kenalog for DML injection 
therapy to identify if more weight can be given to the claims made by this research and give 
more evidence towards the favouring of one steroid. 
 
Conclusion   
This research demonstrates that conservative treatment is currently used for DML and found 
to be successful and injection therapy is occurring within that conservative treatment plan. 
The benefit from injection therapy reported by respondents is similar to previous research but 
could be influenced by injection exposure and potentially steroid choice. Overall a consensus 
is starting to appear regarding dosage, steroid and administration; however differences arise 
when comparing geographical guidelines to CSP and NICE guidelines.  
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Appendix 1 
 
   
 
A Survey to Explore the Current use of Injection Therapy as Part of a Conservative 
Treatment Plan for Degenerative Meniscal Lesions within UK Based, Injection Trained 
Physiotherapy Members of the Society of Musculoskeletal Medicine. 
Instructions 
Many thanks for taking time to complete this survey. 
For each section please see if the questions apply to you. 
If yes, please answer all questions within that section.  
Each question will indicate how many answers are required. 
 
Consent 
Before answering any questions, do you give consent to complete the survey and allow your 
response to be used for data analysis knowing that at all times no personal identification will 
be used and all responses will be anonymous? 
Yes  
No  
 
Part I: Demographics  
 
All participants please answer all of this sections questions; selecting only one answer 
per question. 
 
 
1)  What is your profession? 
  
• Physiotherapist 
• GP/ Doctor 
• Other healthcare professional 
2)  How many years have you been qualified in your profession? 
  
• 0-5 
• 6-10 
• 11+ 
 
 
  
3)  How many years have you been a member of SOMM? 
  
• 0-5 
• 6-10 
• 11+ 
 
4)  
 
Where in the UK do you practice? 
  
• South West 
• South East 
• Midlands 
• North West 
• North East 
• Scotland 
• Northern Ireland 
• Wales 
   
5)   How many years have you been qualified as an injection therapist?  
  
• 0-1 
• 2-5 
• 6-10 
• 11+ 
6)  On average how many steroid injections do you administer in one month? 
  
• 0 
• 1-2 
• 3-5 
• 6-10 
• 11+ 
7)  
On average how many knee joint steroid injections do you administer in 
one month? 
  
• 0 
• 1-2 
• 3-5 
 Part II: Treatment  
 
All participants please answer this section’s questions. 
 
 
• 6-10 
• 11+ 
8)  
When diagnosing a degenerative meniscal lesion, which option(s) do you 
utilize? 
(Select as many answers which apply to you) 
 
• 
 • Conservative eg: subjective and objective assessments. 
 
• 
 • Refer for Magnetic Resonance Imaging (MRI). 
 
• 
 • Refer to orthopaedics for arthroscopy solely to diagnose. 
9)  
 
Once a degenerative meniscal lesion has been diagnosed, treatment is 
patient specific but which option do you most commonly utilise?  
(Select one answer only) 
  
• Always treat conservatively first no matter what, but if unsuccessful refer 
to orthopaedics. 
• Treat conservatively first unless the knee is clinically locked and cannot 
be unlocked manually therefore refer to orthopaedics. 
• Refer to orthopaedics straight away but try conservative treatment whilst 
they wait for an appointment. 
• Always refer to orthopaedics straight away without trying any 
conservative treatment. 
10)  
You decide conservative treatment is indicated, which of the following 
modalities do you utilise?  
(Select as many answers which apply to you) 
  
• Injection therapy. 
• Grade A mobilisations. 
• Grade B mobilisations. 
• Grade C mobilisations. 
• Transverse frictions of the joint line(s). 
• Electrotherapy. 
 • Acupuncture. 
• Taping.  
• Manual distractions of the knee joint (SOMM technique). 
• Manual distractions of the knee joint (not SOMM technique). 
• Exercises. 
• Advice. 
• Advise patient to see GP to discuss NSAID’s and analgesia. 
• Other: 
Please specify______________________________________________ 
• I do not use conservative treatment. 
 
11)  
As a qualified injection therapist, if you do not currently use injection 
therapy as part of your conservative treatment plan for degenerative 
meniscal lesions, please state why?  
(Select as many answers which apply to you) 
  
• Unable to inject in my place of work due to current polices and 
guidelines, including the departments current practice to not inject for 
this pathology. 
• Unable to inject in my place of work due to lack of specialist equipment 
eg: adrenaline. 
• Do not feel confident injecting as a whole. 
• Do not feel confident injecting for this pathology. 
• Not enough training on the area. 
• Do not feel injection therapy works for this pathology. 
• Not enough evidence/ research to show that injection therapy is 
beneficial for this pathology. 
• Already use a combination of other conservative treatments which work 
well therefore no need to inject. 
• Do not use any conservative treatment for this pathology and refer 
straight to orthopaedics. 
• Other: 
Please specify______________________________________________ 
• N/A because I already use injection therapy for degenerative meniscal 
lesions. 
12)  
If you do not currently use injection therapy for degenerative meniscal 
lesions, would you consider it? 
 Part III: Injection Therapy 
 
Please answer the following questions in this section ONLY if you currently use 
injection therapy for degenerative meniscal lesions; if you do not please move onto the 
surgical and conclusion sections. 
 
(Select one answer only). 
  
• Yes, if the answer(s) identified in question 11 were resolved. 
• No. 
• N/A because I already use injection therapy for this pathology. 
13)  
What type of steroid do you use the most when injecting a degenerative 
meniscal lesion? 
(Select one answer only). 
  
• Depomedrone. 
• Adcortyl. 
• Kenalog. 
• Prednisolone. 
• Other: 
Please specify____________________________________________ 
 
14)  
For the steroid you chose in question 13, what dosage do you administer, 
per injection for this pathology? 
(Select one answer only) 
  
• 10mg. 
• 20mg. 
• 30mg. 
• 40mg. 
• 50mg. 
• More than 50mg. 
15)  
Under your Patient Specific/Group Directive (PSD/ PGD), do you combine 
the steroid with local anaesthetic? 
(Select one answer only) 
  
• Yes, I mix in same syringe. 
• Yes, but I inject the steroid and local anaesthetic separately. 
  
• Yes, I use a pre mix solution. 
• No, I just inject steroid. 
16)  
What needle insertion approach do you take? 
(Select as many answers which apply to you) 
  
• Lateral aspect of patella. 
• Medial aspect of patella. 
• Anterior portals of the knee. 
• Through actual joint line of the knee. 
17) 
  
 
Do you currently find injection therapy to be beneficial for degenerative 
meniscal lesions? 
(Select one answer only) 
  
• Yes: all the time. 
• Yes: most of the time. 
• Yes: sometimes. 
• No. 
18)  
When injecting for a degenerative meniscal lesion, which of the following 
benefits do you feel you are achieving? 
(Select as many answers which apply to you) 
  
• Pain relief. 
• Inflammation reduction. 
• Increase range of movement. 
• Improve function of patient. 
• Settling a flare of an already degenerative structure. 
• Delays further degeneration of meniscus. 
• Needle insertion causes traumatic bleeding of knee (intra-articular) 
leading to increased healing secondary to increased blood flow. 
• Needle insertion causes traumatic bleeding of meniscus (trephination) 
leading to increased healing secondary to increased blood flow. 
• Resolving symptoms of an arthritic knee joint which is causing the pain 
not the meniscus. 
• Other: 
Please specify______________________________________________ 
    
19)  
After injection, how long do you leave before you review? 
(Select one answer only) 
  
• Less than 1 week. 
• 1-2 weeks. 
• 3-4 weeks. 
• 5-6 weeks. 
• More than 6 weeks. 
• I do not review. 
 
20)  
 
At your review appointment the patient is better than before but not back 
to pre-lesion level of pain and function, do you re-inject? 
(Select one answer only) 
  
• Yes I would re-inject at that time because I got some benefit from the 
first injection therefore they could further improve with a second. 
• If the patients improvements were enough that they could self-manage I 
would not re-inject at the time but wait until their symptoms potentially 
worsened then inject. 
• If the patients improvements were enough that they could self-manage I 
would not re-inject at the time but continue with other conservative 
treatment until their symptoms potentially worsened then inject. 
• No, I would use other conservative options. 
• No because my PSD/ PGD does not allow it. 
• No, I would refer to orthopaedics. 
 
21)  
If at your review appointment the patient has had no benefit, do you re-
inject? 
(Select one answer only) 
  
• Yes, because I would want to make sure an injection was not beneficial 
and two attempts would give me a better understanding than one. 
• No, I would consider other conservative options. 
• No because my PSD/ PGD does not allow it. 
• No, I would refer on to orthopaedics. 
22)  
Would you inject the same knee more than 3 times a year? 
(Select one answer only) 
 All participants please answer the following questions. 
Part IV: Surgical 
• Less than 6 weeks. 
• 6 weeks to 3 months. 
• 4 to 6 months. 
• 7 to 12 months. 
• Greater than 12 months. 
• I did not select the unsuccessful conservative option in question 22. 
Part V: Conclusion  
 
  
• Yes, I would inject the knee as many times as needed, whenever needed, 
no matter what. 
• Yes, but only if it was beneficial to the patient and they were not fit for 
surgical intervention.  
• No I would consider other conservative options after 3 injections. 
• No, I would refer to orthopaedics after 3 injections.  
23)  
When referring a patient with a degenerative meniscus to orthopedics for 
surgical intervention what are your criteria? 
(Select as many answers which apply to you) 
  
• Any patient with a clinically locked knee that cannot be unlocked 
manually. 
• Any patient that has attempted conservative treatment including injection 
therapy but has been unsuccessful. 
• If there is a degenerative meniscal lesion on imaging I refer on, no matter 
what. 
• Patient asks to be referred on. 
• All degenerative meniscal lesions no matter what are referred on. 
 
24)  
If you selected the unsuccessful conservative treatment option from 
question 23, how long do you use conservative treatment for 
degenerative meniscal lesions before you deem it unsuccessful? 
(Select one answer only) 
25)  
Do you feel degenerative meniscal lesions can be treated with conservative 
treatment as part of routine physiotherapy practice? 
 (Select one answer only) 
 Many thanks for taking time out of your busy day to complete this survey, your response will 
directly help address the research and is thoroughly appreciated. 
 
 
 
 
 
 
 
 
 
  
• Yes, always. 
• Yes, unless surgical criteria is indicated. 
• No. 
26)  
Do you feel injection therapy can be a regular part of the conservative 
treatment for degenerative meniscal lesions? 
 (Select one answer only) 
  
• Yes, always. 
• Sometimes. 
• No. 
   
